Home › Trial NCT00091689
Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions
- Trial IDNCT00091689
- StatusCompleted
- PhasePhase 1
- Study typeInterventional
- SponsorPfizer
- Enrollment—
- Start date2004-09
- ConditionsMelanoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.